Imatinib Sandoz

Imatinib, the active ingredient in Imatinib Sandoz, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is employed in the treatment of chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumours. GNH USA supplies Imatinib Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib Sandoz targets specific tyrosine‑kinase driven cancers and is indicated for the following conditions: - Chronic myeloid leukemia (CML): reduces malignant cell proliferation and achieves durable molecular responses. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves remission rates when combined with chemotherapy. - Gastrointestinal stromal tumour (GIST): inhibits tumor growth driven by KIT or PDGFRA mutations.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Muscle cramps: intermittent tightening of skeletal muscles. - Fatigue: generalized tiredness. - Diarrhoea: loose stools, usually self‑limited. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Severe neutropenia: marked reduction in white blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: reduced heart function, especially in patients with pre‑existing disease. - Pulmonary hypertension: increased pressure in lung arteries. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Tumour lysis syndrome: rapid tumour cell breakdown causing metabolic disturbances.

Patients should be monitored closely for safety concerns before and during therapy. - Blood count monitoring: perform complete blood counts regularly to detect cytopenias. - Liver function assessment: check hepatic enzymes prior to initiation and periodically thereafter. - Cardiac evaluation: assess baseline cardiac status and monitor for signs of heart failure. - Hypersensitivity awareness: discontinue if severe allergic reactions occur. - Pregnancy considerations: avoid use unless benefits outweigh potential risks, as safety data are limited. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with other medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise imatinib plasma levels. - Potent CYP3A4 inducers (e.g., rifampicin, carbamazepine): can markedly reduce drug exposure. - Anticoagulants (e.g., warfarin): may increase bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam, tacrolimus): may require dose adjustments. - QT‑prolonging agents (e.g., quinidine, sotalol): monitor cardiac rhythm. - Vaccines (live attenuated): consider timing to avoid reduced vaccine efficacy.